Shares of Bionano Genomics (BNGO) surged 6.01% in pre-market trading on Wednesday, following a bullish initiation from HC Wainwright. The biotechnology company, which specializes in genome analysis solutions, caught investors' attention after receiving a favorable analyst rating.
HC Wainwright initiated coverage on Bionano Genomics with a "Buy" rating and set an ambitious price target of $10. This price target suggests significant upside potential from the stock's previous closing price. The positive analyst outlook appears to be the primary driver behind the stock's pre-market rally.
The new coverage adds to the overall positive sentiment surrounding Bionano Genomics. According to FactSet, the company now has an average rating of "overweight" from analysts, with a mean price target of $7. This latest development underscores growing optimism about Bionano's prospects in the genomics sector and its potential for future growth.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。